Peter Flynn

Tom Farrell

Artiva Biotherapeutics, Inc. Common Stock

EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived extracellular vesicles (EVs) and formulates proprietary therapeutic vaccines to enhance cancer treatment efficacy. self-described.

EV Therapeutics

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Metric
Company Name	Artiva Biotherapeutics, Inc. Common Stock	EV Therapeutics	Therini Bio	Li Lab of Computational Cancer Immunology
Symbol	ARTV
MSH ID	COM:ARTIVABIO	COM:EVTHERAPEUTICS	COM:THERINIBIO	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector		Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry		Biotechnology	Biotechnology	Biotechnology
Country		US	US	US
Stage
Employee Count		1
Website		evtherapeutics.com	therinibio.com	lilab-utsw.org
LinkedIn			therinibio
Founders

Metric
Market Cap	105.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	33.49M
Revenue (LTM)
Revenue (NTM)
Gross Profit	33.49M
EBITDA	-29.11M
Operating Income	-30.67M
Net Income	-27.70M
EPS	-1.58
Diluted EPS	-1.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-25.95
EBITDA Margin	-0.87
Net Profit Margin	-24.74
Return on Equity	0.18
Return on Assets	-0.34
Return on Capital Employed	-0.40

ARTV

COM:ARTIVABIO

Artiva Biotherapeutics

Last Close

10.88

22/11 21:00

Market Cap

105.10M

Beta: -

Volume Today

36.36K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.48
P/B Ratio	-1.14
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.54K
EV Multiple	-8.29

Metric
Days Sales Outstanding	507.17
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.01

Metric
Operating Cash Flow	-47.43M
Free Cash Flow	-50.69M
Cash Flow to Debt	-1.80
Operating Cash Flow/Sales	-23.65
Free Cash Flow Yield	-0.12

Metric
Cash & Equivalents	53.50M
Accounts Receivable	-510K
Inventory
Goodwill
Debt to Capitalization	-0.09
Debt to Assets	0.18
Current Ratio	6.35
Quick Ratio	6.35

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.61
R&D to Revenue	20.91
SG&A to Revenue	6.04